Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820279 | 0.82 | NOTUM (0.69) | NOTUMCYP19A1HSP90AB1HDAC1P2RX7 | |
| SCHEMBL2821391 | 0.81 | NOTUM (0.68) | NOTUMCYP19A1S1PR1HSP90AB1HDAC1 | |
| SCHEMBL13819978 | 0.80 | ALDH1A1 (0.48) | CYP19A1HSP90AB1ALDH1A1TSHRAADAT | |
| SCHEMBL16206205 | 0.79 | NOTUM (0.73) | NOTUMCYP19A1HSP90AB1HDAC1 | |
| SCHEMBL2822823 | 0.78 | NOTUM (0.62) | NOTUMCYP19A1S1PR1HSP90AB1HDAC1 | |
| SCHEMBL6980467 | 0.77 | NOTUM (1.00) | NOTUMCYP19A1HSP90AB1HDAC1 | |
| SCHEMBL19211427 | 0.77 | NOTUM (0.67) | NOTUMP2RX7 | |
| SCHEMBL2821939 | 0.76 | NOTUM (0.57) | NOTUMCYP19A1S1PR1HSP90AB1HDAC1 | |
| SCHEMBL2820182 | 0.76 | NOTUM (0.73) | NOTUMCYP19A1HDAC1 | |
| SCHEMBL12885309 | 0.76 | NOTUM (0.73) | NOTUMCYP19A1HSP90AB1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | NOTUM 815/4885CYP19A1 296/4885S1PR1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.